Tabula Rasa HealthCare Inc (NASDAQ:TRHC) – Equities researchers at William Blair cut their Q4 2018 EPS estimates for shares of Tabula Rasa HealthCare in a research note issued to investors on Tuesday, December 4th. William Blair analyst R. Daniels now forecasts that the company will earn $0.08 per share for the quarter, down from their previous forecast of $0.09.

Tabula Rasa HealthCare (NASDAQ:TRHC) last issued its quarterly earnings results on Tuesday, November 6th. The company reported $0.26 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.19 by $0.07. The business had revenue of $54.42 million during the quarter, compared to analysts’ expectations of $52.87 million. Tabula Rasa HealthCare had a positive return on equity of 7.63% and a negative net margin of 13.49%. The firm’s revenue for the quarter was up 66.3% compared to the same quarter last year. During the same period in the previous year, the company posted $0.08 earnings per share.

Several other research analysts also recently commented on the stock. Zacks Investment Research upgraded shares of Tabula Rasa HealthCare from a “sell” rating to a “hold” rating in a research report on Thursday. Piper Jaffray Companies restated an “overweight” rating and set a $80.00 price objective on shares of Tabula Rasa HealthCare in a research report on Thursday. BidaskClub upgraded shares of Tabula Rasa HealthCare from a “hold” rating to a “buy” rating in a research report on Wednesday, November 28th. Chardan Capital boosted their price objective on shares of Tabula Rasa HealthCare from $77.00 to $91.00 and gave the company a “buy” rating in a research report on Wednesday, November 7th. Finally, Cantor Fitzgerald restated a “buy” rating and set a $99.00 price objective on shares of Tabula Rasa HealthCare in a research report on Tuesday, November 6th. Two research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $82.50.

Shares of TRHC stock opened at $73.49 on Wednesday. Tabula Rasa HealthCare has a 1 year low of $27.31 and a 1 year high of $91.16. The company has a market capitalization of $1.48 billion, a P/E ratio of -1,837.25, a P/E/G ratio of 6.84 and a beta of 2.53. The company has a debt-to-equity ratio of 0.28, a current ratio of 0.49 and a quick ratio of 0.46.

In related news, President Orsula V. Knowlton purchased 7,500 shares of the stock in a transaction dated Monday, November 12th. The stock was bought at an average cost of $65.00 per share, for a total transaction of $487,500.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Calvin H. Knowlton sold 8,000 shares of the company’s stock in a transaction on Monday, October 8th. The stock was sold at an average price of $74.22, for a total transaction of $593,760.00. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 50,000 shares of company stock valued at $3,655,920. Company insiders own 14.00% of the company’s stock.

Large investors have recently made changes to their positions in the company. Mount Yale Investment Advisors LLC acquired a new position in shares of Tabula Rasa HealthCare during the second quarter worth $111,000. Meadow Creek Investment Management LLC acquired a new position in shares of Tabula Rasa HealthCare during the second quarter worth $115,000. Envestnet Asset Management Inc. acquired a new stake in Tabula Rasa HealthCare in the second quarter valued at $130,000. Pinebridge Investments L.P. acquired a new stake in Tabula Rasa HealthCare in the second quarter valued at $181,000. Finally, Piedmont Investment Advisors LLC acquired a new stake in Tabula Rasa HealthCare in the second quarter valued at $206,000. Institutional investors own 74.88% of the company’s stock.

About Tabula Rasa HealthCare

Tabula Rasa HealthCare, Inc operates as a healthcare technology company in the United States. It offers medication risk management, pharmacy cost management, and medicare risk adjustment services. The company offers its technology-enabled products and services to prescribers, pharmacists, and healthcare organizations for medication risk management and risk adjustment.

Recommended Story: Fiduciary

Receive News & Ratings for Tabula Rasa HealthCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tabula Rasa HealthCare and related companies with MarketBeat.com's FREE daily email newsletter.